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Abstract
Glucocorticoid concentrations are a balance between
production under the negative feedback control and diurnal
rhythm of the hypothalamic–pituitary–adrenal (HPA) axis
and peripheral metabolism, for example by the enzyme
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1),
which catalyses the reduction of inactive cortisone
(11-dehydrocorticosterone (11-DHC) in mice) to cortisol
(corticosterone in mice). Reductase activity is conferred
upon 11b-HSD1 by hexose-6-phosphate dehydrogenase
(H6PDH). 11b-HSD1 is implicated in the development of
obesity, and selective 11b-HSD1 inhibitors are currently under
development. We sought to address the concern regarding
potential up-regulation of the HPA axis associated with
inhibition of 11b-HSD1. We assessed biomarkers for allele
combinations of 11b-HSD1 andH6PDHderived fromdouble
heterozygous mouse crosses. H6PDH knock out (KO)
adrenals were 69% larger than WT while 11b-HSD1 KO
and double KO (DKO) adrenals were w30% larger than
WT – indicative of increased HPA axis drive in KO animals.
ACTH-stimulated circulating corticosterone concentrations
were 2.2-fold higher in H6PDH KO animals andw1.5-fold
higher in 11b-HSD1 KO and DKO animals compared with
WT, proportional to the observed adrenal hypertrophy. KO of
H6PDH resulted in a substantial increase in urinary DHC
metabolites in males (65%) and females (61%). KO of
11b-HSD1 alone or in combination with H6PDH led to
significant increases (36 and 42% respectively) in
urinary DHC metabolites in females only. Intermediate
11b-HSD1/H6PDH heterozygotes maintained a normal
HPA axis. Urinary steroid metabolite profile by gas chro-
matography/mass spectrometry as a biomarker assay may be
beneficial in assaying HPA axis status clinically in cases of
congenital and acquired 11b-HSD1/H6PDH deficiency.
Journal of Endocrinology (2012) 214, 367–372
Introduction
11b-Hydroxysteroid dehydrogenase type 1 (11b-HSD1) is a
34 kDa enzyme anchored in the endoplasmic reticulum (ER)
membrane, with its catalytic domain projecting into the
ER lumen (Odermatt et al. 1999). In vitro, 11b-HSD1
is catalytically bidirectional, displaying both dehydrogenase –
inactivation of cortisol (mice – corticosterone) to cortisone
(mice – 11-dehydrocorticosterone (11-DHC)) – and
oxoreductase (cortisone to cortisol) activities (Agarwal et al.
1989). Conversely, 11b-HSD2 acts as a dehydrogenase
(Shams et al. 1998). In vivo, 11b-HSD1 activity has a strong,
NADPH-dependent directional preference for reduction of
cortisone to cortisol. This activity is facilitated by the enzyme
hexose-6-phosphate dehydrogenase (H6PDH), which con-
verts glucose-6-phosphate to 6-phosphogluconate and
maintains a high NADPH/NADPC ratio sufficient to
permit 11b-HSD1-mediated cortisone reduction (Bujalska
et al. 2005, Lavery et al. 2006, Zielinska et al. 2011). Indeed,
H6PDH and 11b-HSD1 have a direct physical interaction in
the ER lumen, with the N-terminal domain of H6PDH
proving sufficient for the regulation of the directionality of
11b-HSD1 activity (Atanasov et al. 2008, Zhang et al. 2009).
In H6PDH knock out (KO) mice, the change in NADPH
provision leads to 11b-HSD1 ‘switching’ its catalytic
preference in vivo from reductase to dehydrogenase activity.
11b-HSD1 and H6PDH are co-expressed in many tissues
including liver, adipose and the CNS (Hewitt et al. 2005,
Gomez-Sanchez et al. 2010) and function to regulate
intracellular glucocorticoid (GC) availability at the pre-
receptor level. There is an intimate relationship between
cortisol secretion as regulated through the hypothalamic–
pituitary–adrenal (HPA) axis and 11b-HSD1-mediated
metabolism to preserve normal circulating concentrations
(Draper & Stewart 2005). This is highlighted in congenital
and acquired deficiency states. In humans, ‘apparent’
cortisone reductase deficiency (ACRD) and ‘true’ CRD is
a continuum of hyperandrogenism with premature puberty
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due to mutations in H6PDH and 11b-HSD1 respectively
(Lavery 2007, Lawson et al. 2011). In this regard, urinary
steroidobolomics have been instrumental in differentiating
ACRD from CRD. In ACRD, as in H6PDH KO mice,
11b-HSD1 assumes dehydrogenase activity, inactivating
cortisol whereas in CRD there is a less severe urine bio-
chemistry phenotype due to a lack of 11b-HSD1 reductase
activity, without a concomitant increase in dehydrogenase
activity (Zielinska et al. 2011). In both, an increased
cortisol clearance rate results in augmented HPA drive
and a compensatory increase in adrenal cortisol secretion.
A consequence of this is ACTH-mediated adrenal androgen
excess driving disease presentation, which manifests in
children as premature pubarche or in later life in females
as hyperandrogenism and polycystic ovary syndrome (Lavery
et al. 2008a, Idkowiak et al. 2011).
11b-HSD1 and H6PDH KO mice have also been valuable
in understanding the role of these enzymes in integrating GC
metabolism and HPA activity. 11b-HSD1 KO mice have
elevated plasma corticosterone and ACTH levels at the
diurnal nadir with a prolonged corticosterone peak –
indicative of abnormal HPA axis control and enhanced
circadian HPA drive (Harris et al. 2001). However, this
phenotype is dependent on the background strain of the mice,
and when the 11b-HSD1KO is crossed in to the C57BL/6J
background, the HPA defects are less pronounced, possibly
as a result of increased hypothalamic GC receptor expres-
sion, increasing feedback sensitivity (Carter et al. 2009).
Furthermore, as H6PDH KO mice display a switch in the
directionality of 11b-HSD1 activity and have greatly
enhanced GC clearance compared with the 11b-HSD1 KO
mice, they display enhanced HPA axis activation, with grossly
enlarged adrenal glands, and elevated nadir and zenith ACTH
and corticosterone levels (Lavery et al. 2007, Rogoff et al.
2007). We have also generated 11b-HSD1/H6PDH double
KO (DKO) mice to examine whether rescue of 11b-HSD1
dehydrogenase activity might prevent myopathy observed
in H6PDH KO mice (Lavery et al. 2008b, Semjonous et al.
2011). DKO mice assumed an 11b-HSD1KO HPA profile
while the myopathy persisted.
GCs can have detrimental effects on metabolic homo-
eostasis, and therapeutic inhibition of 11b-HSD1 and/or
H6PDH has been proposed as a potential strategy to
ameliorate a range of disease states such as obesity, metabolic
syndrome and hepatic steatosis (Tomlinson & Stewart 2005).
11b-HSD1 inhibitors are currently in phase II clinical trials
(Boyle & Kowalski 2009), and a number of animal studies
have been conducted in which 11b-HSD1 inhibitors appear
to have efficacy (Alberts et al. 2003, Hermanowski-Vosatka
et al. 2005). However, there is some concern that inhibition
of 11b-HSD1 results in activation of the HPA axis that may
negate any beneficial metabolic effects, through the increased
secretion of adrenal cortisol (offsetting the deficit induced
by the inhibitor) and increased adrenal androgen output.
Though mice have no actual capacity to generate adrenal
androgen, surrogate markers of HPA axis activity and GC
metabolism can act as useful biomarkers of the potential
implication of inhibitor use in humans.
We have evaluated that a urinary steroidobolomic bio-
marker of 11b-HSD1 activity using gas chromatography/
mass spectrometry (GC/MS; Krone et al. 2010, Chan et al.
2011) assessed adrenal function using ACTH stimu-
lations tests in all possible allele combinations of offspring
derived from 11b-HSD1/H6PDH double heterozygote
(HET) crosses.
Materials and Methods
Materials
ACTH was purchased from Sigma (cat. no. A-0298). The
corticosterone enzyme immunoassay kit was from Enzo Life
Sciences, Exeter, UK. Lithium heparin tubes were purchased
from Sarstedt, Leicester, UK.
Design
Animal procedures were approved under the British Home
Office Animal (Scientific Procedures) Act 1986 and
conducted in accordance with our project licence and Local
Ethics Committee approval. Mice were group housed under
controlled temperature (21–23 8C) and light (12 h light:12 h
darkness cycle; lights on at 0700 h) with constant access to
regular rodent chow and water. 11b-HSD1 KO and H6PDH
mice and the double heterozygous crosses have previously
been described in detail (Lavery et al. 2006, Semjonous
et al. 2011). Briefly, 11b-HSD1 HET/H6PDH HET mice
were bred to generate all conceivable intermediate genotypes.
Pups were weaned at 3 weeks of age, with female pups being
moved to separate holding cages. For male adrenal weight
data, nZ8/genotype was used and for corticosterone and
ACTH stimulation testing nZ12/genotype. Urine was
collected from mice on a continuous basis until killing
nZ5–6/genotype.
Analysis of urinary steroidobolomic profile
Urine samples were collected from male and female mice
as described previously (Lavery et al. 2006). Samples were
pooled from the same mouse. Using GC/MS, the ratio of
11-OH to 11-oxo metabolites was analysed, as described
previously (Lavery et al. 2006, Krone et al. 2010, Semjonous
et al. 2011).
Measurement of basal and ACTH-stimulated circulating
corticosterone
Corticosterone was measured basally and following the
administration of 1 unit (10 mg) ACTH/100 g mouse by
i.p. injection. Trunk blood samples were collected in lithium
heparin tubes following killing by decapitation between
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0900 and 1000 h. Serum samples were collected and snap
frozen in liquid nitrogen following centrifugation at
13 000 r.p.m. for 10 min. Adrenals were dissected and
weighed. Corticosterone levels were determined using a
corticosterone enzyme immunoassay kit.
Adrenal weights
Adrenals were dissected and weighed following killing by
decapitation between 0900 and 1000 h.
Statistical analysis
Analysis of corticosterone concentrations was performed
using non-linear regression of data in Prism 4 (GraphPad).
Urinary steroid, circulating corticosterone and adrenal
weight data are shown as the meanGS.D. One-way
ANOVA followed by Bonferroni’s multiple comparison
post hoc test was performed using SPSS to compare between
groups for urinary steroid, circulating corticosterone and
adrenal weight data.
Results
Sex-specific differences in urinary steroidobolomic profile
Urinary steroid 11-DHC metabolites were measured and are
displayed as percentage 11-DHC metabolites from total GC
metabolites (Figs 1 and 2). In male 11b-HSD1 KO mice, we
observed an elevated level of urinary 11-DHC metabolites
compared with control (w18 vsw6% respectively); this was
true for all genotypes in which homozygosity for 11b-HSD1
was present. However, in females, the phenotype was
more striking, with 11-DHC consistently 40–45% for all
genotypes in which a homozygosity for 11b-HSD1 was
present (Fig. 1A). This suggests that females have a
different set point in terms of 11b-HSD1-mediated cortico-
sterone metabolism.
In male and female H6PDH KO mice, we observed
a significant increase in urinary 11-DHC metabolites
(65% increase in H6PDH KO males compared with WT
males), and this was true for all H6PDH homozygous
genotypes (Fig. 1B). DKO animals are essentially
a phenocopy of 11b-HSD1 KOs for males (17.2 vs 16.8%
11-DHC metabolites) and females (48.4 vs 43% 11-DHC
metabolites) as a result of the loss of dehydrogenase activity,
normalising the effect of H6PDH loss on 11-DHC
metabolite levels. Single or double 11b-HSD1/H6PDH
heterozygous male and female mice have urinary 11-DHC
metabolite profiles that are essentially similar to those of WT
animals (w10 vs 6.2% andw8.3 vs 6.6% respectively; Fig. 2).
Circulating corticosterone levels in male 11b-HSD1 and
H6PDH KO animals
Basal 0900 h corticosterone was not different between WT,
11b-HSD1 KO and H6PDH KO or DKO mice. Upon
ACTH stimulation, corticosterone levels were significantly
increased compared with basal levels, across all genotypes
(Fig. 3). 11b-HSD1 KO- and DKO-stimulated cortico-
sterone levels were similar, with both achieving 1.5-fold
higher stimulated levels compared with WT. By contrast,
H6PDH KO-stimulated corticosterone levels were substan-
tially (2.2-fold) higher than control and those of 11b-HSD1
KO (1.4-fold) or DKO (1.5-fold). However, the observed
increases did not reach statistical significance.
Adrenal weights in male 11b-HSD1 and H6PDHKO animals
11b-HSD1 KO animals had significantly (27%) larger adrenals
than WTanimals (Fig. 4A). H6PDH KO animals were found
to have significantly (69%) larger adrenal weights than WT,
11b-HSD1 KO (33%) and DKO (28%) animals. DKO
Figure 1 (A) Urinary steroid metabolite profiles ofWT vs 11b-HSD1
KO/DKO mice. Urine samples were collected fromWT, 11b-HSD1
KO and DKO mice of both sexes using filter paper as in Materials
and Methods section. Urinary steroids were subsequently extracted
and analysed by GC/MS. Urinary steroid metabolites are shown
as percentage 11-DHC metabolites as a proportion of total GC.
**P!0.01 (nO4/group) between WT and KO of same sex;
##P!0.01 (nO4/group) between sexes of same genotype; *P!0.05
(nO4/group) between WT and KO of same sex. (B) Urinary steroid
metabolite profiles of WT vs H6PDH KOmice. Urine samples were
collected from WT and H6PDH KO mice of both sexes on a daily
basis using filter paper and were analysed as in (A). **P!0.01
(nO4/group).
Figure 2 Urinary steroid metabolite profiles of WT vs 11b-HSD1
HET/H6PDH HET mice. Urine samples were collected from WT
and 11b-HSD1/H6PDH HET mice of both sexes on a daily basis
using filter paper and were analysed as in (Fig. 1A).
Biomarkers of HPA axis activity in mice . L ABRAHAMS, N M SEMJONOUS and others 369
www.endocrinology-journals.org Journal of Endocrinology (2012) 214, 367–372
animals are essentially a phenocopy of 11b-HSD1 KO animals
with significantly higher adrenal weights than WT animals
(32%; Fig. 4A). Interestingly, 11b-HSD1 HET and H6PDH
HET adrenal weights are similar to WT adrenal weights
(2.3 and 2.4 vs 2.4 mg respectively), suggesting that loss of
one 11b-HSD1 or H6PDH allele is insufficient for eliciting
any impact on adrenal weight (Fig. 4B). 11b-HSD1 KO/
H6PDH HET adrenal weights are also significantly greater
than those ofWTanimals (48%; Fig. 4B), as anticipated due to
the complete loss of 11b-HSD1 activity, irrespective of the
H6PDH genotype. 11b-HSD1 HET/H6PDH KO adrenal
weights are significantly larger than those of WT (twofold)
and of mice of all other genotypes.
Discussion
The loss of one or more 11b-HSD1/H6PDH alleles has
a variable effect on GC metabolism, as revealed by the
urinary steroidobolomic profile of mice of different
11b-HSD1/H6PDH genotypes. H6PDH KO, 11b-HSD1
KO and DKO animals were shown to have increased urinary
11-DHC levels relative to WT levels, indicative of reduced
regeneration of active GCs (Semjonous et al. 2010) and our
data corroborate these findings. In general, H6PDH KO
animals display greater levels of urinary 11-DHC metabolites
than 11b-HSD1 KO animals (Fig. 1A). 11b-HSD1 KO
animals, in turn, have greater levels of urinary 11-DHC
metabolites than WT animals. In the absence of H6PDH,
oxoreductase activity is no longer conferred upon 11b-HSD1
and dehydrogenase activity predominates (Lavery et al. 2006),
so 11-DHC metabolites rise. By contrast, 11b-HSD1 KO
animals have loss of both oxoreductase and dehydrogenase
activities. Basal WT urinary GC metabolites are comparable
between males and females as shown in Fig. 1A. Interestingly,
the effect of KO of 11b-HSD1 is sex specific, with male KOs
having the milder phenotype. Renal and colonic 11b-HSD2
activity is lower in female mice compared with male mice
(Condon et al. 1997). Global 11b-HSD1 activity is also lower
in female humans and rats (Low et al. 1993, Toogood et al.
2000). It is therefore conceivable that male and female mice
have sex steroid-mediated differences in 11b-HSD1 and/or
11b-HSD2 activity set point that become apparent upon
ablation of 11b-HSD1 activity, although the ultimate reason
for the observed sexual dimorphism remains obscure.
11b-HSD1/H6PDH HETs and double HETs have a
urinary 11-DHC profile that is comparable to that of WT
animals (Fig. 2). Loss of one 11b-HSD1 and/or one H6PDH
allele therefore seems to be insufficient for eliciting a
significant change in the urinary 11-DHC profile of mice.
Adrenal weight fluctuates daily under ACTH stimulation
(Harno & White 2010), and chronic ACTH drive on the
adrenal gland induces hyperplasia as a mechanism to
accommodate increased demand. Adrenal size is therefore a
marker of the state of ACTH drive, as exemplified in
individuals with congenital adrenal hyperplasia (e.g. CYP21
deficiency) where chronic ACTH drive causes hyperplasia
of the adrenal cortex (Krone et al. 2005). H6PDH KO,
11b-HSD1 KO and DKO animals have enlarged adrenal
glands compared with control counterparts. H6PDH KO
mice have the largest adrenals, in-keeping with markedly
elevated ACTH levels (Rogoff et al. 2007). By comparison,
11b-HSD1 KO and DKO have smaller adrenals and of an
equivalent size to each other, reflecting the differing status of
11b-HSD1 activity (Semjonous et al. 2011). These data
support previous studies that found the adrenal weights of
11b-HSD1 KO mice on a C57/Bl6J background to be
significantly higher than those of WT animals (Carter et al.
2009). Although increased weight is likely to be due to
Figure 3 Corticosterone levels in ACTH-stimulated and -unstimulated
male animals. Mice were either left unstimulated or stimulated
with ACTH at 1 unit (10 mg)/100 g. 11b-HSD1 KO, H6PDH KO and
DKO animals display elevated levels of circulating corticosterone
relative to WT levels, which is indicative of enhanced HPA axis
drive. However, the mean differences between groups were not
found to be statistically significant (nO4/group).
Figure 4 (A) Adrenal weights of male WT vs HSD1 KO/H6PDH
KO/DKO animals. Mice were killed and adrenals were dissected
and weighed. **P!0.01 (nO4/group) between WT and KOs.
##P!0.01 (nO4/group) between H6PDH KO and all other
genotypes. (B) Adrenal weights of male WT vs 11b-HSD1
HET/H6PDH HET animals. Mice were killed and adrenals were
dissected and weighed as in (A). **P!0.01 (nO4/group) between
HSD1 KO/H6PDH HET and HSD1 HET/H6PDH KO vs all other
genotypes. ##P!0.01 (nO4/group) between HSD1 HET/H6PDH
KO vs all other genotypes.
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adrenal hyperplasia, we have not carried out histological
analysis of adrenal tissue and cannot refute the possibility that
hypertrophy is causal.
Combinations of 11b-HSD1/H6PDH heterozygous
genotypes have adrenal weights that are similar to those of
WT animals. Therefore, loss of one 11b-HSD1 allele and/or
one H6PDH allele appears to be insufficient to elicit a
significant change in adrenal weight and again concurs with
the urinary data; therefore, heterozygosity has no significant
impact on the HPA axis.
Circulating corticosterone levels are determined by an
interplay between adrenal production, diurnal rhythm and
peripheral 11b-HSD1-mediated regeneration in a range of
tissues. Previous studies have shown increased circulating
levels of corticosterone in 11b-HSD1 KO and H6PDH
KO animals, relative to WT levels (Harris et al. 2001, Lavery
et al. 2007, Rogoff et al. 2007). Other studies report no
such elevation in circulating corticosterone levels, possibly as
a function of the inherent variability of the measurement
and the numbers assessed (Semjonous et al. 2010). For
example, Harris et al. (2001) have assayed serum corticoster-
one levels pre- and 2h post-i.p. injection of corticosterone
(5 mg/kg) – to measure HPA axis feedback. This method is
not directly comparable to ours and may explain the
discrepancy in the results obtained. We were unable to
demonstrate differences in nadir corticosterone levels. Upon
ACTH stimulation, circulating corticosterone levels were
significantly elevated after 1 h in all groups. The general
pattern of stimulation correlated with the degree of adrenal
hyperplasia, with H6PDH KO mice having 43% higher
corticosterone than 11b-HSD1 KO or DKO mice, which
were also 48% elevated over WT, implying functional
hyperplasia reflecting genotype. Again, these differences
failed to reach statistical significance.
Overall, H6PDH KO, 11b-HSD1 KO and DKO animals
appear to have increased HPA axis drive compared with
WT animals. H6PDH KO animals display the most marked
up-regulation of the HPA axis while 11b-HSD1 KO animals
show a milder enhancement. DKO animals essentially are
a phenocopy of 11b-HSD1 KO animals and HETs
have a normal HPA status. We propose a combinatorial
approach to measuring HPA axis status under conditions of
11b-HSD1 and/or H6PDH deficiency in vivo, including
characterisation of the urinary steroidobolomic profile by
GC/MS alongside measurement of circulating corticosterone
levels and adrenal weights. The increased adrenal weight
observed in 11b-HSD1 and H6PDH KO mice reflects
the adrenal hypertrophy characteristic of clinical cases in
which 11b-HSD1 is defective, as in ACRD (Cooper &
Stewart 2009). There are, of course, caveats associated with
extrapolating findings from murine studies to the clinical
situation in humans. Indeed, there is even variation in
phenotype between mouse models (Carter et al. 2009).
However, it is hoped that the approach established here for
profiling biomarkers of HPA axis status will prove useful in
informing the optimisation of 11b-HSD1 and/or H6PDH
inhibitors. It is conceivable that the therapeutic use of such
inhibitors be tailored to patient requirements, on the basis
of genotype and sex. A review of the animal and human data
by Harno & White (2010) suggests that inhibitors will have
minimal impact on the HPA axis. Concordantly, loss of one
11b-HSD1 allele plus one H6PDH allele has no discernable
impact on HPA axis biomarkers; therefore, it is likely that
50% inhibition of 11b-HSD1 would have no deleterious
effect on the HPA axis in either males or females. Further
translational studies are required in order to clarify the effects
of inhibition of 11b-HSD1 and/or H6PDH upon HPA axis
status in humans.
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